All resources

April 24, 2026

The value of the innovative pharmaceutical industry – A report summary

This summary of a study by Deloitte combines a traditional economic impact analysis with targeted assessments of health system impacts […]

Learn more | View

February 24, 2026

Increasing access to innovative medicines

Written Submission for the Pre-Budget Consultations in Advance of the 2026-2027 New Brunswick Budget

Learn more | View

February 18, 2026

Increasing access to innovative medicines

Written Submission for the Pre-Budget Consultations in Advance of the 2026 Newfoundland and Labrador Budget

Learn more | View

February 06, 2026

Pre-budget submission 2026

Innovative Medicines Canada (IMC) is pleased to contribute to the Quebec government’s consultations on its 2026-27 budget. Availability of and […]

Learn more | View

January 30, 2026

Increasing access to innovative medicines

Written Submission for the Pre-Budget Consultations in Advance of the 2026 Ontario Budget January 2026

Learn more | View

January 15, 2026

Increasing access to innovative medicines

Written Submission for the Pre-Budget Consultations in Advance of the 2026 Alberta Budget

Learn more | View

December 15, 2025

Increasing access to innovative medicines

Written Submission for the Pre-Budget Consultations in Advance of the 2026 Nova Scotia Budget

Learn more | View

August 01, 2025

Increasing access to innovative medicines

Written Submission for the Pre-Budget Consultations in Advance of the Upcoming Federal Budget

Learn more | View

June 12, 2025

Open letter

Learn more | View

May 06, 2025

The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (736 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).

Learn more | View

March 10, 2025